{
    "nct_id": "NCT03427476",
    "official_title": "CTT1057, a Small Molecular Inhibitor of Prostate Specific Membrane Antigen (PSMA), as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma (RCC): A Pilot Study",
    "inclusion_criteria": "* Patients age ≥18 years old\n* Histologically confirmed renal cell carcinoma\n* Adequate organ function including:\n* - Platelet count of > 50,000/mm3\n* - Neutrophil count of > 1000/mm3\n* - Serum Cr < 1.5 x ULN or estimated GFR > 60 ml/min based upon Cockroft-Gault equation\n* - Proteinuria < 1 g/24 hours based upon 24 hour urine collection or spot urine protein/creatinine ratio\n* - AST and ALT < 2.5 x ULN (< 5 x ULN in patients with known liver metastases)\n* - Total bilirubin < 1.5 x ULN (< 3 x ULN in patients with known/suspected Gilbert's disease)\n* ECOG performance status of 0 or 1\n* Able to provide written informed consent and willing to comply with protocol requirements\n* No contra-indication to MR including severe claustrophobia, incompatible aneurysm clips or cardiac pacemaker\n* For participants of childbearing potential, not pregnant, and use of effective contraceptive methods during the trial and within 6 months following radiotracer injection\n* Cohort A only: Presence of at least three distinct metastatic lesions by standard imaging including whole body bone scan + cross-sectional imaging of the abdomen and pelvis obtained within 12 weeks prior to protocol scan\n* Cohort B only: (N = 5 evaluable patients): Planned nephrectomy within 12 weeks following protocol scan\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with or with a history of uncontrolled bleeding diathesis\n* Inadequate venous access per assessment of treating health care provider\n* Receipt of radioisotope within 5 physical half-lives prior to trial enrollment\n* Prior treatment with alpha radiation therapy (Radium Ra 223 chloride; Xofigo™) during the previous 60 days\n* Have a medical condition or other circumstances that, in the opinion of the investigator would significantly decrease the chances of obtaining reliable data, achieving the study objectives, or completing the trial.\n* Prior history of any other malignancy within past three years, except melanomatous skin cancer or carcinoma in situ.",
    "miscellaneous_criteria": ""
}